Kwality Pharmaceuticals Limited Q3 FY26 results deck summary

Results deck of 12 Feb 2026, summarised by AI from the filing.

Q3 FY26 revenue ₹123.4 cr (+46.2% YoY) and PAT ₹16.0 cr (+87.8% YoY); FY27 targets revenue ₹650+ cr and 25% EBITDA margin.

Key takeaways

1. Q3 FY26 revenue Revenue ₹123.4 cr (Q3FY25: ₹84.4 cr, +46.2%).
2. FY27 targets Targets revenue ₹650+ cr, EBITDA ~₹160 cr and 25% EBITDA margin in FY27.
3. Margin expansion Margins will go up by 300 bps by FY27.
4. Regulated markets Initiated supplies to Mexico and South Africa; completed EU-GMP, Russian, and Ukraine audits.
5. Receivable stretch Receivable stretch from higher share of export and CDMO contracts with milestone-based billing and longer credit cycles.

Original filing on BSE

Kwality Pharmaceuticals Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Earnings call (10 Aug 2026), Results deck (10 Aug 2026)
• Q4 FY26: Earnings call (19 May 2026), Results deck (19 May 2026)
• Q3 FY26: Results deck (12 Feb 2026)
• Q4 FY25: Results deck (5 Jun 2025)